Navigation Links
Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Date:9/23/2009

SAN FRANCISCO, Sept. 23 /PRNewswire-FirstCall/ -- Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year. With 3,690 patients, the SPIRIT IV trial is one of the largest randomized clinical trials between two drug eluting stents.

In the trial's primary endpoint, XIENCE V demonstrated a statistically significant 38 percent reduction in TLF compared to TAXUS (4.2 percent for XIENCE V vs. 6.8 percent for TAXUS, p-value = 0.001). TLF is defined as a composite measure of important efficacy and safety outcomes for patients and is defined as cardiac death, heart attack attributed to the target vessel (target vessel myocardial infarction), and ischemia-driven TLR (ID-TLR). The standard was established to harmonize the definition of major adverse cardiac events across various drug eluting stent trials. XIENCE V also demonstrated a statistically significant 46 percent reduction in TLR (repeat procedure) compared to TAXUS (2.5 percent for XIENCE V vs. 4.6 percent for TAXUS, p-value=0.001). TLR is one of the major secondary endpoints of the SPIRIT IV trial. The groundbreaking results were presented today by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center, during the 2009 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

In addition to demonstrating superiority in the primary endpoint of TLF and major secondary endpoint of TLR, XIENCE V demonstrated an impressive low rate of stent thrombosis (blood clots) at one year. Per protocol definition, XIENCE V demonstrated an observed 80 percent reduction in
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
4. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
5. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
6. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
7. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
8. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
9. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
10. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
11. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... N.J. , Aug. 3, 2015 Ortho ... has been named Chief Corporate Brand and Communications ... firm,s executive leadership team, Bouryal will lead the company,s ... builds on its transition to an independent company by ... report to Chairman and Chief Executive Officer Dr. ...
(Date:8/3/2015)... 3, 2015 Cooperative ... military surgical research and top-tier universities for ... to severe wound treatments for critical-care patients ... medicine and tissue-engineered skin substitute advancements.  Biotech ... in focus are Amarantus Bioscience Holdings, Inc. ...
(Date:8/3/2015)...  BioElectronics Corporation (OTC Pink: BIEL), maker of consumer ... Andrew J. Whelan , President will be interviewed by ... at 9am EDT on Wednesday, August 5 th .  ... http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ Mr. Whelan ... company,s flagship product, ActiPatch Therapy, is achieving in the ...
Breaking Medicine Technology:Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2
... Dec. 21, 2010 Generational Equity, a leading ... mergers, acquisitions, strategic growth initiatives, business valuation and ... B-Pharm, Inc. dba Remedies Pharmacy, headquartered in Carrollton, ... closed on October 26, 2010.  Managing Director, Terry ...
... Dec. 21, 2010 Zimmer Holdings, Inc. (NYSE and ... announced that it has completed the acquisition of Beijing ... Zimmer,s presence in the emerging Chinese market.   ... Zimmer family," said David C. Dvorak, President and CEO ...
Cached Medicine Technology:Generational Equity Announces Sale of B-Pharm, Inc. dba Remedies Pharmacy to a Private Investment Group 2Zimmer Finalizes Acquisition of Chinese Orthopaedic Implant Leader Beijing Montagne Medical Device Co., Ltd. 2
(Date:8/3/2015)... Detroit, Mich (PRWEB) , ... August 03, 2015 , ... ... this country has declined, according to a new publication released today by the AAMC ... of black male college graduates over the past three decades, the number of black ...
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data Interchange ... to create efficiencies in healthcare information exchange, announced the release of its findings from ... Human Services (HHS) Secretary, WEDI shared survey results and recommendations , ...
(Date:8/3/2015)... ... ... to an opinion piece published July 28 by the Washington Post, the conventional ... loss may not be accurate. While this system may work for some people, the author ... based both on the individual and at what point that person is in their weight ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay ... claims in which a claimant alleged to have suffered an arterial blood clot including ... control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. In ...
(Date:8/3/2015)... ... August 03, 2015 , ... BESLER Consulting today announced the ... , The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and ... launch of their Readmissions Analytics product was selected as one of four finalists ...
Breaking Medicine News(10 mins):Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2
... and France signed a landmark cooperative treaty here Thursday ... expected by practitioners to help in the fight against ... cooperate in academic and clinical TCM research, setting new ... practice and developing new TCM products, said the document ...
... city's eastern fringe towards the airport, a signboard on the ... by Maneka Gandhi's People for Animals (PFA). ... day comes true. This sprawling pound aims to restore the ... focuses on anti-rabies vaccination for the canines. ,"We ...
... can prevent [chronic diseases], more people can live longer.',Rapid advances ... are bringing// closer the time when many people can achieve ... Dr. Pascal Goldschmidt, dean of the University of Miami Miller ... we will see diagnostic tools and therapies that will change ...
... in Los Angeles, it was reported that AIDS cases have ... Jaffe, a professor of medicine at Oxford University in England, ... ,He also called for a new approach to ... emphasized on the scientific approach rather than moral and religious ...
... women have been asked to keep a strict watch on ... , The appeal has come from UK’s government watchdog group ... , According to them, one in every seven women ... pregnancy. This refers also to the ‘baby blues’ that quite ...
... it is possible to use a resin filter to ... infected animal, //a finding that has major implications for ... associated with variant Creutzfeldt-Jakob disease, mad cow disease, scrapie ... transfusions. ,Dr. Ruben Carbonell, Frank Hawkins Kenan ...
Cached Medicine News:Health News:An Anti-rabies Campaign With Bite 2Health News:An Anti-rabies Campaign With Bite 3Health News:Genetics Might Engineer Path to Successful Aging 2Health News:'Baby Blues’-no Tiny Proble 2Health News:Researchers Develop Resin Beads That Capture Mad Cow Disease Agent From Blood 2
Speculum can be used for any type of eye surgery. Arms of speculum lie flat due to joint between blade and arms. Features quick locking mechanism....
Pediatric model. Spring-controlled spread of blades with locking mechanism. Dull finish. Blades: 11 mm....
Fenestrated blades with screw-controlled spread. Dull finish. Blades: 15 mm....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: